These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9730170)

  • 21. Factor V Leiden: to test or not to test, that is the debate.
    Makris M
    Blood Transfus; 2012 Jul; 10(3):255-6. PubMed ID: 22889814
    [No Abstract]   [Full Text] [Related]  

  • 22. The discovery of activated protein C resistance.
    Dahlbäck B
    J Thromb Haemost; 2003 Jan; 1(1):3-9. PubMed ID: 12871530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
    Gessoni G; Valverde S; Valle L; Caruso P; Gessoni F; Valle R
    Blood Transfus; 2017 Oct; 15(6):562-567. PubMed ID: 28287382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].
    Jastrzebska M; Bałszan-Kowalska I; Ciechanowicz A; Bińczak-Kuleta A; Falkowski A; Chełstowski K
    Pol Arch Med Wewn; 2003 Jun; 109(6):579-88. PubMed ID: 14567090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple retinal arteriolar occlusions associated with coexisting primary antiphospholipid syndrome and factor V Leiden mutation.
    Dori D; Beiran I; Gelfand Y; Lanir N; Scharf J; Miller B; Brenner B
    Am J Ophthalmol; 2000 Jan; 129(1):106-8. PubMed ID: 10653428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotype and genotype expression in pseudohomozygous R2 factor V.
    Kalafatis M; Simioni P; Bernardi F
    Blood; 2001 Sep; 98(6):1988-9. PubMed ID: 11565539
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
    Glueck CJ; Wang P; Fontaine RN; Tracy T; Sieve-Smith L; Lang JE
    Am J Cardiol; 1999 Sep; 84(5):549-54. PubMed ID: 10482153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interpreting results from Factor V Leiden mutation analysis: a cautionary note.
    Sinclair GD; Poon MC
    Clin Appl Thromb Hemost; 2013; 19(1):106-7. PubMed ID: 23034579
    [No Abstract]   [Full Text] [Related]  

  • 30. APC-PCI complex concentration is higher in patients with previous venous thromboembolism with Factor V Leiden.
    Strandberg K; Stenflo J; Nilsson C; Svensson PJ
    J Thromb Haemost; 2005 Nov; 3(11):2578-80. PubMed ID: 16241958
    [No Abstract]   [Full Text] [Related]  

  • 31. Factor V Leiden and venous thrombosis in a 4-yr-old girl with Behçet's syndrome.
    Ihle J; Kümmerle-Deschner J; Orlikowsky T; Albert E; Niethammer D; Dannecker GE
    Rheumatology (Oxford); 2000 Feb; 39(2):209-10. PubMed ID: 10725075
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of factor V Leiden and prothrombin 20210A in patients with retinal artery occlusion.
    Weger M; Renner W; Pinter O; Stanger O; Temmel W; Fellner P; Schmut O; Haas A
    Eye (Lond); 2003 Aug; 17(6):731-4. PubMed ID: 12928685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinical audit of congenital thrombophilia investigation in tertiary practice.
    Favaloro EJ; Mohammed S; Pati N; Ho MY; McDonald D
    Pathology; 2011 Apr; 43(3):266-72. PubMed ID: 21436638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for resistance to activated protein C and the mutant gene for factor V:Q506 in patients with central retinal vein occlusion.
    Vine AK; Samama MM
    Am J Ophthalmol; 1997 Nov; 124(5):673-6. PubMed ID: 9372721
    [No Abstract]   [Full Text] [Related]  

  • 35. Activated protein C resistance assay and factor V Leiden.
    Prüller F; Weiss EC; Raggam RB; Cervar-Zivkovic M; Renner W; Wagner J; Michaelis S; März W; Mangge H
    N Engl J Med; 2014 Aug; 371(7):685-6. PubMed ID: 25119624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion.
    Cruciani F; Moramarco A; Curto T; Labate A; Recupero V; Conti L; Gandolfo GM; Balacco Gabrieli C
    Clin Ter; 2003; 154(5):299-303. PubMed ID: 14994919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Retinal vein occlusion and resistance to activated protein C].
    Scat Y; Morin Y; Morel C; Haut J
    J Fr Ophtalmol; 1995; 18(12):758-62. PubMed ID: 8745708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central retinal vein thrombosis associated with resistance to activated protein C.
    Dhôte R; Bachmeyer C; Horellou MH; Toulon P; Christoforov B
    Am J Ophthalmol; 1995 Sep; 120(3):388-9. PubMed ID: 7661212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel factor V mutation causes a normal activated protein C ratio despite the presence of a heterozygous F5 R506Q (factor V Leiden) mutation.
    Prüller F; Raggam RB; Mangge H; Truschnig-Wilders M; Matzhold EM; Weiss EC; Hasiba B; Summers KL; Renner W; Siegert G; Kostka H
    Br J Haematol; 2013 Nov; 163(3):414-7. PubMed ID: 23957718
    [No Abstract]   [Full Text] [Related]  

  • 40. Pulmonary embolism following head positioning for retinal reattachment surgery in a young patient with factor V leiden mutation.
    Au Eong KG; Beatty S; Thomas W; Sen V; Turner GS
    Arch Ophthalmol; 2000 Sep; 118(9):1300-1. PubMed ID: 10980782
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.